Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference

Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the William Blair Growth Stock Conference from June 1-3, 2021. The company will present on June 3 at 9:00 am ET. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes OVA1® plus and ASPIRA GenetiX™ testing, aimed at improving gynecologic health outcomes. For more details, visit their website.

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below:

William Blair Growth Stock Conference
Date:	Tuesday, June 1 – Thursday, June 3, 2021
Presentation:	Thursday, June 3 at 9:00 am ET
Webcast:	https://wsw.com/webcast/blair58/awh/1770080

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (Nasdaq: AWH) (formerly known as Vermillion, Inc.) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

FAQ

What is the date of the William Blair Growth Stock Conference for AWH?

The William Blair Growth Stock Conference will be held from June 1-3, 2021.

When will Aspira Women’s Health present at the conference?

Aspira Women’s Health will present on June 3, 2021, at 9:00 am ET.

Where can I access the webcast for Aspira Women’s Health's presentation?

The presentation can be accessed via the webcast link: https://wsw.com/webcast/blair58/awh/1770080.

What is the focus of Aspira Women’s Health?

Aspira Women’s Health focuses on innovative testing options for women's health, including ovarian cancer risk assessment and treatments for pelvic diseases.

What products does Aspira Women’s Health offer?

Aspira offers products like OVA1® plus and ASPIRA GenetiX™ testing for risk assessment and gynecologic health.